Breaks Categories: News

ThursdayMar 30, 2023 12:22 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Strategic Board Appointment of Gerry David

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced the appointment of Gerry David to its advisory board. David is best known for his five-year tenure as CEO at zero-calorie fitness drink maker Celsius Holdings Inc., where he spearheaded a turnaround that resulted in a global sales explosion, influx of capital from notable strategic investors, and a rise in market capitalization that increased shareholder value 35-fold by exceeding $9 billion. “I have seen countless products…

Continue Reading

WednesdayMar 29, 2023 12:25 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in Upcoming Virtual Investor Event

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at an upcoming Virtual Investor GBM Spotlight Event. The online event is scheduled for April 4, 2023, at 4:30 p.m. ET. The event will include a live, moderated video webcast with members of CNS Pharmaceuticals management, including CEO John Climaco; the panel will also include key opinion leader, Michael Weller, MD. Weller is an acclaimed neuro-oncologist who currently serves as chair of the Department of Neurology at the University Hospital in Zurich,…

Continue Reading

MondayMar 27, 2023 2:38 pm

BioMedNewsBreaks – Titan Partners Group LLC Announces Appointment of Life-Sciences Expert Dr. David Sans

Titan Partners Group, a division of American Capital Partners LLC (“Titan Partners”), today announced that Dr. David Sans has joined the firm as head of healthcare. Dr. Sans will lead the team that covers companies in the biopharmaceuticals, diagnostics, medtech and specialty pharmaceuticals sectors. “We are excited to bring in David Sans to join Titan Partners and lead our healthcare practice as we continue to expand our footprint and capacity in this sector,” said Michael Sands, Titan Partners co-founder and partner. “David’s expertise in life sciences makes him a valuable addition to our team. Titan Partners is committed to building…

Continue Reading

MondayMar 27, 2023 10:59 am

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Fibromyalgia

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has filed a provisional patent application titled “Methods and Compositions for Pain Management.” The methods and compositions described in the patent application can be used in ameliorating pain, including chronic pain such as fibromyalgia, which is a chronic condition that occurs in approximately 2% of the United States general population. Fibromyalgia is the initial target indication for the company’s drug, SP-26. “This provisional patent application supports our multi-pronged strategy for advancing SP-26 into the clinic,” said Silo Pharma CEO…

Continue Reading

FridayMar 24, 2023 11:24 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Poised to Enable Expedited Care for Heart Attack Patients

HeartBeam (NASDAQ: BEAT) is developing the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. “By applying a suite of proprietary algorithms to simplify vector electrocardiography (‘VECG’), the HeartBeam platform will enable patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately. HeartBeam AIMIGo(TM) is the first and only credit-card-sized,…

Continue Reading

WednesdayMar 22, 2023 12:58 pm

BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) to Attend Investor Summit

IGC Pharma (NYSE American: IGC) (aka India Globalization Capital Inc.) today announced that its Chief Executive Officer Ram Mukunda and Principle Financial Officer Claudia Grimaldi will attend the Investor Summit on Wednesday, March 29, 2023. According to the update, Mukunda and Grimaldi will deliver a virtual company presentation at 11:30 a.m. ET and be available for virtual one-on-one meetings throughout the day. Interested investors should visit https://ibn.fm/AiqIk to register for the webinar and view the live presentation. To view the full press release, visit https://ibn.fm/M3rGV About IGC Pharma Inc. IGC Pharma is a clinical stage biotechnology company developing advanced cannabinoid-based…

Continue Reading

WednesdayMar 22, 2023 12:47 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Subsidiary Receives Official Approval to Move Forward with Phase 1 Clinical Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, announced that its Australian entity, FSD Pharma Australia Pty Ltd., has been approved to move forward with a key phase 2 clinical trial. The approval comes from the Alfred Ethics Committee in Australia, and the trial is designed to evaluate FSD Pharma’s Lucid-201 as a novel drug candidate for the potential treatment of major depressive disorder (“MDD”). Lucid-Psych is being developed outside of Australia by Lucid Psycheceuticals Inc.,…

Continue Reading

WednesdayMar 22, 2023 10:08 am

BioMedNewsBreaks – Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP) Tech Spotlighted in Article in Peer-Reviewed Translational Medicine Journal

Coeptis Therapeutics (NASDAQ: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, was spotlighted in the peer-reviewed “Journal of Translational Medicine.” The company’s SNAP-CAR technology was recognized in an article that detailed advances in modulating chimeric antigen receptor (“CAR”)-T cell activity for improved safety, efficacy and flexibility. SNAP-CAR is a multiantigen chimeric antigen receptor T cell technology that can be adapted to different cancer indications, including hematologic and solid tumors. Titled “Tuning CARs: Recent Advances In Modulating Chimeric Antigen Receptor (‘CAR’) T Cell Activity for Improved Safety, Efficacy and Flexibility,” the article outlined the efforts and collaborations that…

Continue Reading

MondayMar 20, 2023 1:05 pm

BioMedNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Rebrands, Including Changing Name to IGC Pharma, as Part of ‘Major Milestone’ Alignment

India Globalization Capital (NYSE American: IGC) (dba IGC Inc.) will begin operating under the name IGC Pharma Inc. (dba IGC), effective March 30, 2023; the name change is one aspect of the company’s rebranding strategy designed to better reflect its strategic focus and vision for the future. IGC’s common stock will trade on NYSE American exchange under the new name on March 31, 2023; the symbol will remain the same: IGC. According to the announcement, the change in name to IGC Pharma better represents the company’s focus as a developer of drug assets for treating diseases, including but not limited to…

Continue Reading

FridayMar 17, 2023 10:40 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q4, FY 2022 Financial Report, Corporate Updates

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, is reporting its operational and financial results for the fourth quarter and full year, ended Dec. 31, 2022. The company has also scheduled an earnings call and webcast for today at 4:30 p.m. ET to discuss the report. A highlight of the report includes the company’s strategic acquisition of LIVMOR assets, including its FDA-cleared Halo+(TM) Atrial Fibrillation Detection System and physician-prescribed integrated patient care platform, three U.S. patents, business contracts and relationships as well as all…

Continue Reading